Ignite Creation Date:
2025-12-24 @ 3:41 PM
Ignite Modification Date:
2026-03-09 @ 2:44 PM
Study NCT ID:
NCT03023592
Status:
UNKNOWN
Last Update Posted:
2017-01-18
First Post:
2017-01-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Iguratimod in Sjögren's Syndrome
Sponsor:
Peking Union Medical College Hospital
Organization:
Study Overview
Official Title:
A Preliminary Efficacy Study of Iguratimod in Patients With Sjögren's Syndrome
Status:
UNKNOWN
Status Verified Date:
2017-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A single-center, self-control, open-label study of efficacy and safety of Iguratimod in patients with Sjögren's Syndrome
Detailed Description:
In this study, patients with Sjögren's Syndrome are enrolled and received Iguratimod 25 mg twice a day for 24 weeks. The differences of ESSPRI (EULAR Sjogren's Syndrome Patient Reported Index) score, ESSPRI(EULAR Sjogren's Syndrome Patient Reported Index) score, unstimulated salivary flow rate, Schirmer's test SF-36 score and HAQ score between baseline and week 24 are evaluated to determine the efficacy of Iguratimod in patients with Sjögren's Syndrome.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: